Opus Genetics positive Phase 1/2 OPGx-BEST1 data, FDA Type C alignment on pivotal trial endpoint

 

Opus Genetics reports positive Phase 1/2 OPGx-BEST1 data and FDA Type C alignment on pivotal trial endpoint

• Positive three- and six-month low-dose Cohort 1 Phase 1/2 OPGx-BEST1 gene therapy data reported.
• Phase 3 OPGx-BEST1 dosing targetedfor 2027 following successful FDA Type C meeting alignment

https://finviz.com/stock?t=IRD&p=d